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Background: Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced
melanoma. TP53 mutations are rare in cutaneous melanoma and hence activation of wild-type p53 is a potential therapeutic
strategy in cutaneous melanoma. Here, we investigated the WIP1 inhibitor, GSK2830371, and MDM2–p53 binding antagonists
(nutlin-3, RG7388 and HDM201) alone and in combination treatment in cutaneous melanoma cell lines and explored the
mechanistic basis of these responses in relation to the genotype and induced gene expression profile of the cells.
Methods: A panel of three p53WT (A375, WM35 and C8161) and three p53MUT (WM164, WM35-R and CHL-1) melanoma cell lines
were used. The effects of MDM2 and WIP1 inhibition were evaluated by growth inhibition and clonogenic assays, immunoblotting,
qRT–PCR gene expression profiling and flow cytometry.
Results: GSK2830371, at doses (p10 mM) that alone had no growth-inhibitory or cytotoxic effects on the cells, nevertheless
significantly potentiated the growth-inhibitory and clonogenic cell killing effects of MDM2 inhibitors in p53WT but not p53MUT
melanoma cells, indicating the potentiation worked in a p53-dependent manner. The siRNA-mediated knockdown of p53
provided further evidence to support the p53 dependence. GSK2830371 increased p53 stabilisation through Ser15
phosphorylation and consequent Lys382 acetylation, and decreased ubiquitination and proteasome-dependent degradation
when it was combined with MDM2 inhibitors. These changes were at least partly ATM mediated, shown by reversal with the ATM
inhibitor (KU55933). GSK2830371 enhanced the induction of p53 transcriptional target genes, cell cycle arrest and apoptosis.
Conclusions: GSK2830371, a WIP1 inhibitor, at doses with no growth-inhibitory activity alone, potentiated the growth-inhibitory
and cytotoxic activity of MDM2 inhibitors by increasing phosphorylation, acetylation and stabilisation of p53 in cutaneous
melanoma cells in a functional p53-dependent manner.
Cutaneous melanoma is the most serious skin malignancy (Miller
and Mihm, 2006) and one of the most common cancers in
developed countries (Torre et al, 2015). The prognosis of
melanoma patients depends on the stage at presentation and the
survival outcomes of patients with advanced stage are extremely
poor (Balch et al, 2009). Both the MAPK (RAS–RAF–ERK)
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(Demunter et al, 2001; Davies et al, 2002) and ARF–MDM2–p53
(Chin, 2003) pathways are critical in melanoma tumourigenesis
and genetic alterations associated with them provide important
druggable targets. The combination of BRAF and MEK inhibitors
has become the standard treatment for unresectable or metastatic
melanoma harbouring a BRAFV600 mutation (Larkin et al, 2014;
Robert et al, 2015). However, a therapeutic strategy targeting the
p53 network has not been established in melanoma and could be a
good option for advanced melanoma patients harbouring no
BRAFV600 mutation (Lu et al, 2014).
The tumour suppressor p53 is a transcription factor that
regulates a number of genes with a broad range of functions,
including DNA repair, metabolism, cell cycle arrest, apoptosis and
senescence (Levine et al, 1991; Wade et al, 2010; Gannon and
Jones, 2012). Mutation of TP53 results in loss of wild-type (WT)
p53 tumour suppressor function and can also have dominant
oncogenic functions (gain-of-function mutations) that are entirely
independent of WT p53, causing cancer cell development, survival
and proliferation (Muller and Vousden, 2013). However, melano-
mas have p53 mutations only in a minority of cases (B20%).
Furthermore, p53 mutations and loss of CKDN2A appear to be
mutually exclusive, possibly reflecting p53 dependence (Hodis et al,
2012; Zhang et al, 2016). Therefore, a therapeutic strategy to rescue
and reactivate p53 function can be envisioned in melanomas that
retain WT p53.
The MDM2–p53 binding antagonists block the p53-binding
pocket of MDM2 and stabilise p53 by preventing MDM2-mediated
ubiquitylation and degradation. This results in activation of the
p53 pathway in p53WT (p53 wild type) rather than p53MUT (p53
mutated) cancer cells, causing cell cycle arrest, apoptosis and
growth inhibition of human cancer cells (Brown et al, 2009).
Nutlin-3 was the first MDM2–p53 binding antagonist to be
developed and shown to have efficacy in vitro and in vivo (Vassilev
et al, 2004; Sachweh et al, 2013; Polanski et al, 2014). The RG7388
(Idasanutlin), an orally available second-generation MDM2–p53
binding antagonist, efficiently suppressed tumour growth in vivo
(Ding et al, 2013); clinical trials of RG7388 are currently ongoing
to investigate the clinical efficacy of MDM2 inhibitors in relapsed
multiple myeloma (NCT02633059), relapsed or refractory acute
myeloid leukaemia (NCT02670044, NCT02545283) and relapsed
or refractory follicular lymphoma or diffuse large B-cell lymphoma
(NCT02624986). The HDM201, a new-generation and highly
potent and selective MDM2 inhibitor, is also under investigation in
early clinical trials (Hyman et al, 2016).
PPM1D encodes wild-type p53-induced phosphatase 1 (WIP1)
that is involved in homeostatic regulation of p53 function and
stability by directly dephosphorylating p53 after cellular stress.
PPM1D is also a direct transcriptional target of p53, thus forming a
negative autoregulatory loop with the p53 network by depho-
sphorylating p53 (Ser15) and other signalling components (such as
ATM (ataxia-telangiectasia mutated), ATR (ataxia telangiectasia
and Rad3-related) and MDM2) involved in p53 post-translational
regulation (Lu et al, 2007; Lowe et al, 2012). GSK2830371
allosterically inhibits the enzymatic activity of WIP1 protein and
also enhances ubiquitin-mediated degradation of WIP1 (Gilmartin
et al, 2014). Preclinical studies have shown that GSK2830371
can enhance p53-mediated tumour suppression by MDM2
inhibitors, nutlin-3 (Esfandiari et al, 2016; Pechackova et al,
2016), nutlin-3a (Sriraman et al, 2016) and RG7388 (Esfandiari
et al, 2016) or by chemotherapy (Gilmartin et al, 2014; Pechackova
et al, 2016).
The aim of the current study was to investigate WIP1 inhibition
(WIP1i), GSK2830371 and MDM2–p53 inhibitors, nutlin-3,
RG7388 and HDM201, alone and in combination treatment
specifically in cutaneous melanoma cell lines and to explore the
mechanistic basis of these responses in relation to the genotype and
induced gene expression of the cells.
MATERIALS AND METHODS
Cell lines and reagents. Cutaneous melanoma cell lines were
routinely cultured using Dulbecco’s modified Eagle’s medium
(DMEM) medium containing 4.5 g l 1 glucose (Sigma-Aldrich,
Gillingham, UK) and supplemented with 10% (v/v) foetal calf
serum. All the cell lines were authenticated by serial tandem repeat
(STR) profiling (NewGene, Newcastle, UK) and tested to confirm
lack of mycoplasma infection. Nutlin-3 was purchased from
NewChem (Newcastle, UK), RG7388 and HDM201 were obtained
from Astex Pharmaceuticals (Cambridge, UK) and GSK2830371
was purchased from Sigma-Aldrich. All compounds were initially
dissolved in DMSO (Sigma-Aldrich) and used to dose cells at a
final concentration of 0.5% DMSO with minimal cytotoxic effects
on cells.
Growth inhibition assay. Melanoma cells were seeded in 96-well
plates 24 h before 72 h of treatment with nutlin-3 RG7388,
HDM201, GSK2830371 or combinations. The cells were fixed
using Carnoy’s fixative followed by Sulforhodamine B (SRB) assay
(Skehan et al, 1990). The GI50 value, the concentration of a
compound that can reduce the growth of the cell population by
50% compared with solvent control, was determined. The details of
the calculation for growth inhibition are described in
Supplementary Information.
Clonogenic assay. Melanoma cell lines were seeded in 6-well
plates and left for 24 h before treatment with MDM2 inhibitors for
72 h, combined with or without WIPi. Fresh medium was replaced
and the cells were fixed after 10–21 days depending on the growth
rates of the cells. The LC50 value, the concentration of a compound
that can reduce the number of colonies by 50% compared with
solvent control, was determined.
Immunoblotting. Cell lysates were harvested by 2% SDS lysis
buffer, heated and sonicated. Equal quantities of protein were
loaded onto and separated by SDS–polyacrylamide gels (4–20%
Mini-PROTEAN TGX Gel, BioRad, Watford, UK). The separated
proteins were transferred and immobilised onto Amersham
nitrocellulose membranes (GE Healthcare Life Science, Amersham,
UK). Primary antibodies against p53 (DO-7) (M7001, Dako,
Glostrup, Denmark), MDM2 (Ab-1) (OP46, Merck Millipore,
Watford, UK), p21WAF1 (EA10) (OP64, Calbiochem, Merck
Millipore), WIP1 (F-10) (sc-376257, Santa Cruz Biotechnology,
Dallas, TX, USA), phospho-p53(Ser-15) (9284, Cell Signaling
Technology, Danvers, MA, USA), acetyl-p53(Lys382) (2525, Cell
Signaling Technology), BAX (2772, Cell Signaling Technology),
GAPDH (14C10) (2118, Cell Signaling Technology) and secondary
goat anti-mouse/rabbit horseradish peroxidase-conjugated anti-
bodies (P0447/P0448, Dako) were used. All antibodies were diluted
in 5% (w/v) non-fat milk or BSA in TBS–Tween. Proteins were
visualised using enhanced chemiluminescence (GE Healthcare Life
Sciences) and X-ray film (Fujifilm, Bedford, UK). Densitometry
was carried out using ImageJ software (National Institutes of
Health, Rockville, MD, USA).
Site-directed mutagenesis and ectopic expression of mutant
p53. The details of site-directed mutagenesis have been described
in a previous study (Esfandiari et al, 2016). The WM35 was
transfected with plasmid cDNA constructs encoding either wild-
type or mutated p53 (S15A or S15D) using Lipofectamine 2000
(Thermo Fisher Scientific, Cramlington, UK) and incubated for
18 h to allow protein expression before collecting lysates for
immunoblotting.
Denaturing immunoprecipitation. Cell lysates were collected by
2% SDS lysis buffer and aliquots were used as input. Non-SDS lysis
buffer was used to dilute to the rest of lysates. A total of 2 mg of
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anti-p53 (sc-126, Santa Cruz Biotechnology), anti-Ub (sc-8017,
Santa Cruz Biotechnology) or normal IgG (sc-2025, Santa Cruz
Biotechnology) was incubated with lysates. Dynabeads (Thermo-
Fisher Scientific) were used for immunoprecipitation according to
the manufacturer’s protocol. Immunoblotting was performed as
above and anti-mouse IgG VeriBlot for IP secondary antibody
(HRP) (ab131368, Abcam, Cambridge, UK) was used.
RNA extraction and qRT–PCR. Total RNA was extracted using
an RNeasy Mini Kit (Qiagen, Hilden, Germany). The RNA purity
and concentration was estimated with an ND-1000 spectro-
photometer (NanoDrop Technologies, Thermo Fisher Scientific).
Complementary DNA was generated using the High-Capacity
cDNA Reverse Transcription Kit (4368814, Thermo Fisher
Scientific) as described by the manufacturer. The qRT–PCR was
carried out using SYBR green RT–PCR master mix (Life
Technologies, Thermo Fisher Scientific) as per the manufacturer’s
guidelines and the following primers:
MDM2: F-50-AGTAGCAGTGAATCTACAGGGA-30 and R-50-
CTGATCCAACCAATCACCTGAAT-30
CDKN1A: F-50-TGTCCGTCAGAACCCATGC-30 and R-50-
AAAGTCGAAGTTCCATCGCTC-30
PUMA: F-50-ACCTCAACGCACAGTACGA-30 and R-50-CTG
GGTAAGGGCAGGAGTC-30
TP53INP1: F-50-TCTTGAGTGCTTGGCTGATACA-30 and
R-50-GGTGGGGTGATAAACCAGCTC-30
FAS: F-50-AGATTGTGTGATGAAGGACATGG-30 and R-50-
TGTTGCTGGTGAGTGTGCATT-30
TNFRSF10B: F-50-ATGGAACAACGGGGACAGAAC-30 and
R-50-CTGCTGGGGAGCTAGGTCT-30
BAX: F-50-CCCGAGAGGTCTTTTTCCGAG-30 and R-50-CC
AGCCCATGATGGTTCTGAT-30
GAPDH: F-50-CAATGACCCCTTCATTGACC-30 and R-50-GA
TCTCGCTCCTGGAAGAT-30.
The qRT–PCR reactions using a total of 20 ng of the cDNA
samples per 10 ml final reaction volume with the standard cycling
parameters were performed and products detected in real time on
an ABI 7900HT system (Applied Biosystems, Foster City, CA,
USA) (Esfandiari et al, 2016). The GAPDH was used as
endogenous control and samples of cells exposed to DMSO
solvent control were used as the calibrator for each independent
repeat, with the formula 2DDCt used to calculate fold changes.
Analysis was carried out using SDS 2.2 software (Applied
Biosystems).
Reverse phase protein arrays. The reverse phase protein arrays
(RPPA) detection of proteins was carried out by ArrayGen UK
(Newcastle, UK) on a collaboration basis. The detailed experi-
mental procedure and technical background are described in
Supplementary Information (Voshol et al, 2009).
Fluorescence-activated cell sorting. After treatment, floating and
adhered cells were pooled and fixed using 70% cold ethanol.
Samples were incubated in 250 ml PBS with 40 mgml 1 propidium
iodide (Sigma-Aldrich) and 20 mgml 1 RNAse A (Sigma-Aldrich)
for 20min in the dark at room temperature, and then were
analysed on a fluorescence-activated cell sorting (FACS) Calibur
flow cytometer using CellQuest Pro software (Becton Dickinson,
Oxford, UK). Cell cycle distribution based on DNA content was
determined using Cyflogic (CyFlo Ltd, Turku, Finland).
Caspase-3/7 activity assay. Melanoma cells were seeded in white
96-well plates and treated for 24 h. Caspase-3/7 enzymatic activities
were measured using a FLUOstar Omega plate reader (BMG
Labtech, Aylesbury, UK) after adding a 1 : 1 ratio of CaspaseGlo-3/
7 reagent (Promega, Southampton, UK) to growth media and
incubating for 30min. All values were expressed as a ratio of signal
relative to solvent control.
Transfection of siRNAs. A total of 40 nM siRNA duplex
(Eurogentec, Lie`ge, Belgium) against TP53 and control noncoding
sequence was transfected by Lipofectamine 2000 (Thermo Fisher
Scientific) in OptiMEM-glutamax serum free media (Thermo
Fisher Scientific). The sequences were designed as follows: Control
SiRNA (SiControl), sense: 50-GCGCGCUUUGUAGGAUUCGd
TdT-30, antisense: 50-CGAAUCCUACAAAGCGCGCdTdT-30; two
alternative TP53 targeted siRNAs (SiP53), SiP53 #1, sense: 50-CC
ACCAUCCACUACAACUAdTdT-30, antisense: 50-UAGUUGUA-
GUGGAUGGUGGdTdT-30, SiP53 #2, sense: 50-CUGGAUGGAGAA
UAUUUCAdTdT-30, antisense: 50-UGAAAUAUUCUCCAUCC
AGdTdT-30.
Statistical analysis. Data were presented as mean±s.e.m. unless
otherwise stated. Statistical tests were carried out using GraphPad
Prism 6 (GraphPad Software, La Jolla, CA, USA) and all P-values
represent paired t-tests of at least three independent repeats.
A P-value of o0.05 was considered as statistically significant.
RESULTS
GSK2830371, at doses showing no growth inhibition alone,
potentiated the effects of MDM2 inhibitors on A375 and WM35
cells. The expression of WIP1 protein after p53 activation was
evaluated by immunoblotting, showing induction of WIP1 was
associated with p53 stabilisation after RG7388 (0.2mM) treatment
for 6 h in p53WT but not p53MUT melanoma cell lines (Figure 1A).
The WIP1i, GSK2830371, was used as a single agent in growth-
inhibitory experiments. Growth inhibition measured by SRB assay
showed that GSK2830371 at concentrations ofp10 mM had no or
minimal growth-inhibitory effect on p53WT (A375, WM35, C8161)
and p53MUT (WM164, WM35-R, CHL-1) melanoma cells
(Figure 1B). Immunoblotting of WM35 cells treated by MDM2
inhibitor (either 5 mM nutlin-3 or 1mM RG7388), combining with
different concentrations of GSK2830371 (Figure 1C), illustrated
that WIP1 protein decreased gradually with increased dosages of
GSK2830371. Phospho-p53 (Ser15) and acetyl-p53 (Lys382) were
probed because phospho-p53 (Ser15) is a direct substrate of WIP1
phosphatase and p53 can be acetylated by CBP/P300 that has been
reported to be recruited after phosphorylation of p53 (Ser15)
(Meek, 2015). Marked increases in phospho-p53 (Ser15) and
acetyl-p53 (Lys382) as a consequence of WIP1 inhibition were
observed. The transcriptional targets of p53, MDM2 and p21
increased modestly after combination treatment with GSK2830371.
To choose an optimal concentration of GSK2830371, growth
inhibition assays were performed for A375 and WM35 treated with
either MDM2 inhibitor (5mM nutlin-3 or 1mM RG7388) combined
with different concentrations of GSK2830371 (Figure 1D–G). Dose-
dependent growth inhibition by GSK2830371 was only found after
p53 activation with nutlin-3 or RG7388. A GSK2830371 concentra-
tion of 2.5mM displayed the best potentiation when combined with
either MDM2 inhibitor and was therefore used for subsequent
experiments to evaluate the role of WIP1 in p53 network responses.
Supplementary Figure S1A shows immunoblotting of A375,
WM35 and C8161 cells treated with MDM2 inhibitor (5 mM nutlin-
3 or 1 mM RG7388) combined with 2.5 mM GSK2830371 for 6 h.
Supplementary Figure S1B shows immunoblotting of A375 and
C8161 cells treated with HDM201 combined with 2.5mM
GSK2830371 for 6 and 24 h. The protein changes were similar to
the findings in Figure 1C. The same treatment was performed on
A375 and phospho-p53 (Ser15) was detected by RPPA. Signifi-
cantly increased phospho-p53 (Ser15) was found after combination
treatment with either nutlin-3 or RG7388 and GSK2830371
(Supplementary Figure S1C). The signals were suppressed by
alkaline phosphatase, validating the antibody used in the RPPA to
be specific for phosphorylated protein.
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GSK2830371 potentiated the growth-inhibitory and cytotoxic
activity of MDM2 inhibitors in a p53-dependent manner.
Growth inhibition and clonogenic survival following treatment
with MDM2 inhibitor (either nutlin-3, RG7388 or HDM201) with
or without GSK2830371 (2.5 mM) combination was evaluated for a
panel of p53WT (A375, WM35 and C8161) and p53MUT (WM164,
WM35-R, CHL-1) melanoma cell lines (Figures 2 and 3 and
Supplementary Figure S2). GSK2830371 enhanced the growth-
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Figure 1. The WIP1 phosphatase induction by p53 activation with either nutlin-3 or RG7388 and inhibition by GSK2830371 (WIP1i). (A) Increase
in WIP1 expression in p53WT but not p53MUT melanoma cell lines by p53 activation with RG7388 (0.2mM) for 6 h (D, DMSO, R, RG7388). (B) Growth
inhibition by SRB assay showed WIP1i atp10 mM has no growth-inhibitory effect on p53WT or p53MUT melanoma cells. (C) Immunoblotting of A375
and WM35 cells treated by MDM2 antagonists (5 mM nutlin-3 or 1 mM RG7388) combined with different concentrations of WIP1i for 6 h. (D–G)
Growth inhibition of A375 and WM35 by either 5 mM nutlin-3 or 1 mM RG7388, combined with different concentrations of WIP1i for 72 h. The %
growth is shown either normalised to DMSO solvent control treatment (D and E) or to the fixed doses of MDM2 inhibitors (F and G).
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inhibitory effects of MDM2 inhibitors in p53WT rather than
p53MUT melanoma cells, showing that potentiation by
GSK2830371 worked in a p53-dependent manner (Figure 2A
and Supplementary Figure S2A). GSK2830371 significantly
decreased the GI50 for nutlin-3, RG7388 or HDM201 compared
with the GI50 for nutlin-3 or RG7388 alone in p53
WT melanoma
cells (Figure 2B and Supplementary Figure S2B).
A clonogenic assay was performed to see whether GSK2830371
can enhance the cytotoxic activity of MDM2 inhibitors. The
GSK2830371 further inhibited colony formation when it was added
to either MDM2 inhibitor in p53WT melanoma cells (Figure 3A
and Supplementary Figure S2C). GSK2830371 significantly
decreased the LC50 for nutlin-3, RG7388 or HDM201 compared
with the LC50 for MDM2 inhibitor alone for A375 or C8161 cells
(Po0.05) and with a similar trend for WM35 (Figure 3B and
Supplementary Figure S2D). Compared with control (DMSO),
there was no significant reduction of colony formation on
treatment by GSK2830371 (2.5 mM) as a single agent (Figure 3C
and D). The potentiation by GSK2830371 in clonogenic assays was
limited to p53WT and was not seen with p53MUT melanoma cells
(Figure 3C).
Increased p53 stabilisation by GSK2830371 through increased
phosphorylation and acetylation when combined with MDM2
inhibitors could be reversed by ATM inhibition. Ubiquitylation
and acetylation happen on the same lysine residues of the
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Figure 2. GSK2830371 (WIP1i) potentiated the growth-inhibitory effect of MDM2 antagonists in a p53-dependent manner. (A) Growth inhibition
measured by SRB assay for p53WT (A375, WM35 and C8161) and p53MUT (WM164, WM35-R, CHL-1) melanoma cell lines treated with different
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WT melanoma cells.
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C-terminal region of p53 and both are mutually exclusive.
Therefore, it was hypothesised that inhibition of WIP1 protein
by GSK2830371 could enhance the stabilisation of p53 through
increasing acetylation and decreasing ubiquitin-mediated degrada-
tion. The lack of obvious change in total p53 protein in the
presence of WIP1 inhibition in Figure 1C was postulated to reflect
saturation of p53 stabilisation following treated by 5 mM nutlin-3
and 1 mM RG7388. Therefore, lower concentrations of nutlin-3 and
RG7388 were tested in combination with GSK2830371. The
resulting immunoblots confirmed that combination of lower
MDM2 inhibitor doses and WIP1i increased p53 stabilisation
compared with the effect of MDM2 inhibitor as a single agent
(Figure 4A and Supplementary Figures S1B and S3). Furthermore,
this increase was associated with higher levels of phosphorylation
(Ser15) and acetylation (Lys382) of p53, and higher expressions of
MDM2 and p21.
To examine whether the phosphorylation of p53 (Ser15) is a key
residue for subsequent C-terminal acetylation of p53, WM35 cells
were transfected with different p53 mutant plasmid constructs,
including WT, S15A and S15D mutations (Figure 4B). After 18 h of
transfection with 1mg plasmid, increased p53 expression was
detected for all three constructs. However, phospho-p53 (Ser15)
could only be detected in cells after WT p53 cDNA transfection
and not p53 mutant transfections, showing the antibody used was
specific against WT p53 (Ser15) phosphorylation. Acetyl-p53
(Lys382) was detected in the cells after p53 (WT) and the S15D
phosphomimetic mutant transfection but not when ser15 was
mutated to the non-phosphorylatable alanine, indicating that Ser15
and its phosphorylation is an essential and sufficient residue for
p53 acetylation.
To evaluate whether WIP1 inhibition by GSK2830371 stabilises
p53 by slowing down its degradation, cycloheximide (CHX) was
used to block de novo protein synthesis (Figure 4C). The C8161
was treated with 0.2 mM RG7388 for 4 h to make p53 accumulate.
The cells were then treated with CHX (100mgml 1) to block
protein synthesis, in the presence or absence of GSK2830371 for 2
and 4 h. Protein lysates were collected for immunoblotting at the
indicated time points. During the 4 h CHX treatment, GSK2830371
slowed down p53 degradation, evidenced by significantly higher
levels of p53 protein with concurrent GSK2830371 treatment than
without GSK2830371 treatment (P¼ 0.02) (Figure 4D and E). To
test whether the degradation is proteasome dependent, A375 cells
were treated with RG7388±WIP1i and MG132 for 6 h. The
MG132 completely prevented the degradation of p53 and masked
any difference in stabilisation of p53 by RG7388±WIP1i
(Figure 4F). Co-immunoprecipitation showed GSK2830371 treat-
ment decreased Ub–p53 by pulling down either p53 or ubiqutin
(Figure 4G).
We next examined whether the p53 (Ser15) phosphorylation
seen following combined treatment with MDM2 inhibitors and
WIP1i is ATM mediated. The A375 cells were treated with 0.2 mM
RG7388±WIP1i and±ATM inhibitor (KU55933 10 mM) concur-
rently for 6 h. The phosphorylation, acetylation and stabilisation of
p53 were reversed by ATM inhibitor, indicating that these changes
are at least in part mediated by basal ATM activity (Figure 4H).
The KU55933 also decreased the growth-inhibitory effects of
MDM2 inhibitors on A375 cells (Supplementary Figure S4).
Paired WM35 and WM35-R cells showed GSK2830371 increased
p53 stabilisation in a p53-dependent manner. The WM35-R is
an MDM2 inhibitor resistant cell line that we have selected from
parental WM35 cells by culturing in medium containing 5 mM
RG7388. Sanger sequencing revealed that WM35-R has a
homozygous TP53 point mutation (1001G4T) resulting in a
Gly334Val amino acid substitution in the p53 protein
(Supplementary Figure S5), which is the hinge between b-strand
(residues 326–333) and a-helix (residues 335–354) regions in the
oligomerisation domain (Kawaguchi et al, 2005). Therefore, this
pair of melanoma cells is useful for exploring p53-dependent
pathway mechanisms in cutaneous melanoma.
Compared with MDM2 inhibitors alone, the combination of
MDM2 inhibitor and GSK2830371 increased p53 phosphorylation
(Ser15), acetylation (Lys382) and stabilisation in WM35 but did
not increase p53 acetylation (Lys382) and stabilisation in WM35-R
(Supplementary Figure S6A). A CHX experiment was performed in
WM35 and WM35-R cells to investigate whether GSK2830371
inhibition slowed down the degradation of p53 only in WM35,
because acetylation was not found in WM35-R (Supplementary
Figure S6B). Interestingly, the mutant p53 in WM35-R cells was
still subject to some degradation; however, after 4 -h of CHX
treatment, GSK2830371 decreased the wt-p53 degradation in
WM35 more than the mut-p53 in WM35-R (Supplementary
Figure S6B).
GSK2830371 increased the mRNA expression of p53 transcrip-
tionally regulated genes when combined with MDM2 inhibitors.
To test the hypothesis that GSK2830371 enhances the transcrip-
tional activity of p53 in cutaneous melanoma cells treated by
MDM2 inhibitors, mRNA expression of candidate genes related to
cell cycle arrest and apoptosis were evaluated by quantitative real-
time PCR (qRT–PCR). The p53WT cells (A375, C8161, WM35)
and one p53MUT cell line, WM35-R, were treated with either 1mM
nutlin-3 or 0.2 mM RG7388, combined with or without
GSK2830371 (2.5 mM) for 6 h.
Overall, nutlin-3 or RG7388 induced expression of candidate
genes and GSK2830371 potentiated the induced genes in p53WT
cells rather than WM35-R. The fold changes of mRNA in response
to MDM2 inhibitors with or without WIP1i were less in WM35
than A375 and C8161 (Figure 5 and Supplementary Figure S7).
Interestingly, WIP1i alone could significantly induce some of the
p53 transcriptional target genes. However, the effects of
GSK2830371 on transcript levels were modest, consistent with
GSK2830371 alone having no or minimal growth-inhibitory effect
in SRB and clonogenic assays (Figures 1B and 3C and D) and with
the lack of obvious changes in p21 and MDM2 proteins in
immunoblotting (Figure 1C and Supplementary Figure S1).
Genes for cell cycle arrest, CDKN1A, and autoregulatory
negative feedback, MDM2, were generally induced to a higher
level by combination treatment with GSK2830371 and MDM2
inhibitors in p53WT cells, except for the RG7388 plus GSK2830371
combination treatment in WM35. Pro-apoptotic BAX, FAS,
PUMA, TNFBSF10B and TP53INP1 genes were also evaluated.
For BAX, the induction was modest even though some of the
differences were statistically significant. This finding was consistent
with another study that showed no significant increase of BAX
expression in ovarian cancer cells treated by 5mM nutlin-3 or
0.5 mM RG7388 for 6 h (Zanjirband et al, 2016). For FAS, PUMA,
TNFBSF10B and TP53INP1 genes in A375 and C8161,
GSK2830371 significantly potentiated the effect of RG7388 on
the expression levels of these genes (Po0.05). GSK2830371 also
showed the same trend for enhancing the effect of nutlin-3 on the
expression of these genes, but the fold changes were mostly not
statistically significant (P40.05).
The WM35 had less fold changes of pro-apoptotic genes than in
A375 and C8161. GSK2830371 appeared to increase the effect of
nutlin-3 treatment in WM35 on the expression of pro-apoptotic
genes, although some of these trends were not statistically
significant (P40.05). The poor potentiation of RG7388 by
GSK2830371 found in WM35 was possibly because the transcripts
of those genes were saturated by RG7388 treatment alone; WM35
treatment with 1 mM RG7388 did not increase more mRNA
expression of MDM2, CDKN1A, PUMA, TNFBSF10B and
TP53INP1 compared with 0.2 RG7388, either with or without
WIP1i (Supplementary Figure S8).
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The effect of combined MDM2 and WIP1 inhibition on cell
cycle distribution and apoptosis. Given that GSK2830371
potentiated the growth inhibition and clonogenic reduction by
MDM2 inhibitors, FACS analysis was carried out to investigate
changes in cell cycle distribution. In addition, sub-G1 events
detected by FACS analysis and caspase-3/7 catalytic activity were
used as indicators of apoptosis. The responses to MDM2 and WIP1
inhibitors were cell line dependent.
In all the cell lines, 2.5 mM GSK2830371 alone did not affect the
cell cycle distribution through 72 h of treatment (Figure 6 and
Supplementary Figures S9 and S10) In general, RG7388 (0.2 mM) or
HDM201 (0.2 mM) treatment of p53WT cells (A375, WM35, C8161)
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decreased the proportion of cells in S phase that was accompanied
by G1-phase increases, with or without G2-phase increases.
Treatment with GSK2830371 further enhanced the changes in cell
cycle distribution markedly when it was combined with MDM2
inhibitors.
Apoptotic responses, shown by increased FACS sub-G1 signals
and caspase-3/7 activity after RG7388 or HDM201 treatment, was
evident for A375 cells but not for WM35 or C8161 cells. The
combination of MDM2 and WIP1 inhibitors significantly
increased the apoptotic response of A375 cells. Cell cycle
distribution was not affected in TP53 mutant WM35-R cells
regardless of the treatment conditions, demonstrating that the
changes in cell cycle distribution observed are p53 dependent.
SiRNA-mediated p53 knockdown. To further investigate the p53
dependence of MDM2 and WIP1 inhibition in cutaneous
melanoma, siRNA-mediated p53 knockdown was performed in
two p53WT melanoma cells, A375 and WM35. The cells were
treated with siRNA for 24 h followed by RG7388 or
HDM201±GSK2830371 treatment. The potentiation of growth
inhibition by GSK2830371 on RG7388 or HDM201 was sup-
pressed by the p53 knockdown (Figure 7).
DISCUSSION
In the current study, we demonstrated that doses of the GSK2830371,
WIP1 inhibitor, with no growth-inhibitory activity nevertheless
potentiated the growth inhibition and cell killing of wild-type p53
cutaneous melanoma cells by MDM2 inhibitors, nutlin-3, RG7388
and HDM201. Mechanistic studies linked this potentiation to
increased phosphorylation, acetylation and decreased ubiquitylation.
This has a twofold effect, resulting in not only increased stabilisation
of p53 but also increased functional activation by the increased post-
translational phosphorylation and acetylation (Figure 8).
Among the three p53WT melanomas investigated in the current
study, we found A375 to be particularly primed to undergo
apoptosis in response to p53 activation rather than the other two
cell lines. This was evidenced by significant increases in sub-G1
signals on FACS cell cycle analysis and caspase-3/7 activity after
combination treatment. The p53-dependent transcription profiles
possibly explain some differences between the A375 and WM35
responses to MDM2 and WIP1 inhibition (Figure 5 and
Supplementary Figure S7). Although p53 expression has generally
been associated with the levels of transcriptional target genes
responsible for cell cycle arrest and apoptosis, apoptosis has been
reported only to proceed in certain conditions, such as achieving a
transcriptional threshold by p53 reactivation or suppression of its
negative regulators (Kracikova et al, 2013; Lu et al, 2013; Khoo
et al, 2014). Therefore, two distinct subgroups of response are
identifiable, depending on whether cells undergo apoptosis or not
after p53 reactivation by MDM2 inhibitors. Irreversible apoptosis
only occurs with some cell types and reversible growth suppression
or senescence without apoptosis is observed with other cell types
(Tseng et al, 2010; Lu et al, 2013). In the current study, inhibition
of WIP1, a negative regulator of p53, potentiated the activation of
p53 in all three p53WT melanoma cell lines through post-
translation modification, but only enhanced apoptosis in A375
cells and did not shift cell cycle arrest to apoptosis in the cells not
primed for apoptosis (WM35 and C8161 in the current study).
Post-translational modification of p53 has critical effects on its
stability and function (Kruse and Gu, 2009). A key post-
translational modification is the phosphorylation of p53 at Ser15,
which is mediated by the ATM and ATR protein kinases, and has
been considered as an initiating event in p53 activation (Saito et al,
2002) by promoting the acetylation of lysine residues of the p53
C-terminal region, through recruitment of p300/CBP histone
acetyltransferase (Gu and Roeder, 1997; Lambert et al, 1998;
Dumaz and Meek, 1999; Reed and Quelle, 2014). The MDM2 can
ubiquitinate the same lysine residues of p53 (Brooks and Gu, 2011;
Reed and Quelle, 2014), and acetylation and ubiquitination are
mutually exclusive. Therefore, p53 acetylation increases its stability
by inhibiting MDM2-mediated ubiquitination of p53 and can
stimulate its sequence-specific DNA binding activity (Gu and
Roeder, 1997; Li et al, 2002).
The WIP1 phosphatase and ATM kinase work antagonistically
on the same p53-related substrates, ATM (Ser1981), MDM2
(Ser395) and p53 (Ser15), to maintain a fine balance of these
proteins in order to regulate the function and stability of p53. For
example, autophosphorylation of ATM (Ser1981) after irradiation
has been shown to stabilise ATM at DNA damage sites and
phosphorylate p53 (Ser15) (So et al, 2009). Ser1981 of ATM is also
a substrate of WIP1 phosphatase (Shreeram et al, 2006) and WIP1
inhibition by GSK2830371 can increase phospho-ATM (Ser1981)
in a non-genotoxic manner (Gilmartin et al, 2014). Following
DNA damage stress, ATM is able to phosphorylate MDM2 at
Ser395 that attenuates degradation of p53 (Khosravi et al, 1999;
Maya et al, 2001). The WIP1 can stabilise MDM2 in an ATM-
dependent manner and also inhibit ubiquitination of MDM2 (Lu
et al, 2007). Therefore, GSK2830371 is an effective non-genotoxic
way of increasing activation of the ATM-mediated network by
inhibition of WIP1 to maintain the phosphorylated state of key
proteins. This is particularly useful when the p53-dependent WIP
phosphatase is induced by non-genotoxic MDM2 inhibitors.
GSK2830371 as a single agent selectively inhibits the growth of
MCF-7 and MX-1 cells, PPM1D amplified breast cancer cells and a
subset of p53WT haematological cancer cell lines (Gilmartin et al,
2014). In one previous report using cells with different PPM1D gene
alterations (gain-of-function mutations, amplification or copy
number gain), all cells except MCF-7 cell were resistant to
GSK2830371 (GI50410mM) as a single agent treatment
(Esfandiari et al, 2016). Consistent with this report, GSK2830371
alone had no obvious growth-inhibitory activity (GI50410mM) in
all of the melanoma cell lines we investigated in the current study
(Figure 1A). Actually, modest phosphorylation of p53 (Ser15)
following treatment with single agent GSK2830371 was detected by
immunoblotting (Figure 4A) and RPPA (Supplementary Figure S1B)
that resulted in a statistically significant but small increase in
transcript level of some genes (Figure 6) and slight induction of p21
protein (Figures 1C and 4A). However, the transactivation of genes
by this small level of p53 phosphorylation was insufficient to have a
significant effect on the growth of the cutaneous melanoma cells.
Previous studies with genotoxic modalities such as ionising or
UV irradiation indicated a model in which resultant phosphoryla-
tion of p53 on Ser15 recruits histone acetyl transferases (HATs) to
acetylate lysine residues in the p53 C-terminal domain (Saito et al,
2002). In the current study, this model was more specifically tested
and shown to be applicable to non-genotoxic treatment with
MDM2–p53 binding antagonists and WIP1 inhibitor, providing a
mechanistic basis for the potentiation. Consistent with a recent
report (Sriraman et al, 2016) using nutlin-3a and GSK2830371, our
results showed that enhanced phosphorylation (Ser15) and
acetylation (Lys382) of p53 were found after non-genotoxic
nutlin-3 and GSK2830371 treatment. Here we extended these
observations to more specific and potent MDM2 inhibitors that are
progressing through clinical trials. In addition, we transfected p53
(Ser15) mutants to prove the Ser15 is the essential and sufficient
residue for p53 acetylation. Furthermore, we investigated the p53
stability after combination treatment in the current study.
The CHX treatment was used to investigate the effect of
acetylation of p53 after GSK2830371 treatment on p53 half-life and
showed p53 levels were increased by slowing down degradation.
The MG132 reversed the change in p53 expression, indicating that
GSK2830371 decreased the proteasomal degradation of p53. Both
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the p53 acetylation leading to inhibition of its ubiquitination by
MDM2 (Li et al, 2002) and WIP1 inhibition by siRNA leading to
decrease in p53 ubiquitination (Lu et al, 2007) are consistent with
our finding that WIP1 inhibition by GSK2830371 stabilised p53 as
a result of the decreased MDM2-mediated ubiquitination shown by
co-immunoprecipitation. When the cells were treated by the lower
concentrations of MDM2 inhibitors, the MDM2 was only partially
inhibited by MDM2 inhibitors, hence p53 acetylation then played a
critical role in p53 stability by antagonising ubiquitiylation
(Figure 4).
GSK2830371 potentiated MDM2 inhibitors to amplify the
expression of p53 transcriptionally targeted genes that are
responsible for cell cycle arrest and apoptosis in p53WT melanoma
cells, but the degree of potentiation was cell line dependent.
Greater potentiation by GSK2830371 was found with A375 and
C8161 cells than for WM35 by qRT–PCR, immunoblotting,
growth inhibition and clonogenic assay. Although combination
treatment stabilised p53 by decreasing degradation in WM35 cells,
the increases in p53-target gene mRNAs and proteins in this cell
line were modest (Figure 5). Consequently, the fold changes in GI50
and LC50 values were more limited. We also checked basal
expressions of MDMX and WIP1 (Supplementary Figure S11) and
showed there was no clear correlation between basal expression
levels and responses to MDM2 and WIP1 inhibition, as MDM4
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was overexpressed in B65% melanoma cases (Gembarska et al,
2012). The results of the current study indicate that the
responsiveness of melanoma cell lines to MDM2 inhibitors and
WIP1i depends to a large part on the fold differences between the
basal and maximal relative transcript levels of downstream p53
transcriptional target genes, and is also likely to be modulated by
the downstream status of pro-survival and anti-apoptotic pathways
(Supplementary Figure S8).
In summary, we report the non-genotoxic potentiation of
nutlin-3 and clinically relevant second-generation MDM2–p53
binding antagonists, RG7388 and HDM201, by the WIP1
phosphatase inhibitor GSK280371, through p53 phosphorylation,
acetylation, stabilisation and increased transcription of p53
regulated genes in a panel of p53WT cutaneous melanoma cell
lines. This combination treatment activated the ATM-mediated
response without DNA damage, highlighting a novel non-
genotoxic therapeutic strategy to further explore for melanoma.
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